Heart failure & cardiomyopathies
Sodium–Glucose Cotransporter 2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: Analyses of Short-Term Efficacy and Safety
Authors' conclusion
Sodium-glucose cotransporter 2 inhibitors were well tolerated by most patients with ATTR-CM and appeared to improve volume status and combat diuretic resistance.
Study context
- Population
- Consecutive patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at a tertiary care centre; median age 79 years, nearly 90% male, 93% on a transthyretin stabilizerPS-matched n = 42 per cohort
- Participants
- 87 vs 95
- Exposure
- SGLT2 inhibitors vs no SGLT2 inhibitor
- SGLT2in = 87
- Controln = 95reference
- Outcome
- Changes in weight, loop diuretic dose and cardiac/renal biomarkers
Methodological detailssingle-centre, tertiary care centre, propensity-score matched analysis
- Single-centre
- Tertiary care centre
- Propensity-score matched analysis
Main finding
As reported in the abstract
Changes from baseline in weight, loop diuretic dose, uric acid and cardiac/renal biomarkers · during follow-up (median 5.6 vs 8.4 months)
- Significantly greater reductions in weight, loop diuretic dose and uric acid with SGLT2i vs controls
- p < 0.001
- eGFR significantly reduced vs controls 1 month after SGLT2i initiation; no significant differences at later timepoints
- p = 0.002
Observational data: associations, not effects.
Safety
- Discontinuation of SGLT2i
- 11.5% · 10 of 87
Original publication
Sodium–Glucose Cotransporter 2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: Analyses of Short-Term Efficacy and Safety. Eur J Heart Fail. Published 15 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →